Form 8-K Salarius Pharmaceuticals For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Salarius Pharmaceuticals faces Nasdaq delisting over stock price
January 2, 2026 5:16 PM ESTSalarius Pharmaceuticals, Inc. (NASDAQ: SLRX) received notice from Nasdaq on December 31, 2025, stating the company fails to meet minimum bid price requirements for continued listing on The Nasdaq Capital Market.
The company's stock closed below $1.00 per share for 30 consecutive business days, violating Nasdaq... More



